Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | F12 | P00748 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | F3 | P13726 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL344671 | 0.84 | — | — | |
| Urea SCHEMBL6098803 | 0.82 | CYP1A2 (0.52) | CYP1A2HTR2AMAOADRD2DRD1 | |
| Hydroxyamine SCHEMBL268551 | 0.81 | CYP1A2 (0.50) | CYP1A2HTR2AMAOADRD2DRD1 | |
| SCHEMBL1525601 | 0.80 | — | — | |
| SCHEMBL109650 | 0.80 | CYP1A2 (0.62) | CYP1A2HTR2AMAOADRD2DRD1 | |
| SCHEMBL22081972 | 0.80 | CYP1A2 (0.62) | CYP1A2HTR2AMAOADRD2DRD1 | |
| SCHEMBL29881712 | 0.80 | — | — | |
| Urea SCHEMBL17710420 | 0.80 | CYP1A2 (0.50) | CYP1A2HTR2AMAOADRD2DRD1 | |
| Acetamide SCHEMBL28035592 | 0.78 | NOTUM (0.48) | CYP1A2HTR2AMAOAADRA2ASLC6A2 | |
| SCHEMBL11106630 | 0.78 | CYP1A2 (0.48) | CYP1A2HTR2AMAOADRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3673911-B1 | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY | UAB RES FOUND (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4281087-A2 | MULTIVALENT CHLOROTOXIN CHIMERIC ANTIGEN RECEPTORS | IN8bio, Inc. (US) | 2023-11-29 | — | — | EP | claimed |
| WO-2022159582-A2 | MULTIVALENT CHLOROTOXIN CHIMERIC ANTIGEN RECEPTORS | IN8bio, Inc. (US) | 2022-07-28 | — | — | WO | claimed |
| CN-113574171-A | Compositions and methods for treating cancer | IN8生物股份有限公司 | 2021-10-29 | — | — | CN | claimed |
| US-20210322475-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UAB RESEARCH FOUNDATION | 2021-10-21 | — | — | US | claimed |
| EP-3877514-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | In8bio, Inc. (US) | 2021-09-15 | — | — | EP | claimed |
| US-20210205361-A1 | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY | Incysus Therapeutics, Inc. | 2021-07-08 | — | — | US | claimed |
| EP-3673911-A1 | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY | The UAB Research Foundation (US) | 2020-07-01 | — | — | EP | claimed |
| US-20200188436-A1 | Compositions and Methods for Cancer Immunotherapy | INNATUS THERAPEUTICS, INC. | 2020-06-18 | — | — | US | claimed |
| US-20200055909-A1 | CHIMERIC CHLOROTOXIN RECEPTORS | THE UAB RESEARCH FOUNDATION | 2020-02-20 | — | — | US | claimed |
| EP-3551657-A1 | CHIMERIC CHLOROTOXIN RECEPTORS | The UAB Research Foundation (US) | 2019-10-16 | — | — | EP | claimed |
| EP-3246042-B1 | DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER | UNIV EMORY (US) | 2019-07-10 | — | — | EP | claimed |
| EP-3500262-A1 | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY | The UAB Research Foundation (US) | 2019-06-26 | — | — | EP | claimed |
| WO-2018107134-A1 | CHIMERIC CHLOROTOXIN RECEPTORS | THE UAB RESEARCH FOUNDATION (US) | 2018-06-14 | — | — | WO | claimed |
| WO-2018035413-A1 | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY | THE UAB RESEARCH FOUNDATION (US) | 2018-02-22 | — | — | WO | claimed |
| EP-3246042-A1 | DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER | Emory University (US) | 2017-11-22 | — | — | EP | claimed |
| EP-2496244-A2 | DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER | Emory University (US) | 2012-09-12 | — | — | EP | claimed |
| WO-2011053750-A2 | DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER | EMORY UNIVERSITY (US) | 2011-05-05 | — | — | WO | claimed |
| US-12005078-B2 | Genetically engineered drug resistant T cells and methods of using the same | THE UAB RESEARCH FOUNDATION (US) | 2024-06-11 | — | — | US | disclosed |
| WO-2011053750-A2 | DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER | EMORY UNIVERSITY (US) | 2011-05-05 | — | — | WO | disclosed |